Study Title
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level (NCT01396070)

Trial Description
The purpose of this study is to learn the effects of an investigational medication, brentuximab vedotin (also known as SGN 35), on patients with mycosis fungoides. Despite a wide range of therapeutic options, the treatments are associated with short response duration, thus this condition is largely incurable. This investigational drug may offer less toxicity than standard treatments and have better tumor specific targeting.

This trial is sponsored by Youn Kim, Stanford University/ Seattle Genetics. [1]

Study Data

  • Condition:
    • Non-Hodgkin Lymphoma
    • Cutaneous Lymphoma
    • Cutaneous T Cell Lymphoma
    • Mycosis Fungoides
    • Sezary Syndrome
  • Interventions:
    • Drugs used in this trial
      • Brentuximab vedotin (Adcetris®; Seattle Genetics)
  • Phase: 0
  • Estimated Enrollment: 36
  • Start: June 2011
  • Estimated Completion: October 2015
  • Last verified: March 2015

Study Schematic


Click here to Return to Drug map

Last Editorial review: July 16, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.